Prospective Pellevé™ Neck Wrinkle Study

NCT ID: NCT01299090

Last Updated: 2016-04-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 49 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-11-30
• Study Completion Date: 2011-09-30

Brief Summary

Use of RF device to treat wrinkles of the neck

Detailed Description

This is a prospective study evaluating the safety and efficacy of two treatments, spaced at 30 day intervals, using the Surgitron® Dual RF™ S5 with the Pellevé™ wrinkle treatment handpiece and Pellevé™ treatment gel for the treatment of neck wrinkles.

Conditions

Facial and Neck Rhytides

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment Group

All subjects enrolled were in the treatment group.

Group Type: EXPERIMENTAL

Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator

Intervention Type: DEVICE

two treatments spaced 30 days apart

Interventions

Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator

two treatments spaced 30 days apart

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• 30-70 years of age
• Subjects with clinical evidence of neck wrinkles moderate to severe in severity as specified by a grade 4-9 on the Fitzpatrick Wrinkle Assessment Scale.
• Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
• Willingness and ability to provide written photo consent and adherence to photography procedures(i.e., removal of jewelry and makeup).
• Willingness and ability to provide written informed consent prior to performance of any study related procedure.

Exclusion Criteria

• Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control.
• Subjects who have had prior exposure to any hyaluronic acid, or any other filler, injection for any purpose in the 12 months preceding study enrollment through the duration of the study.
• Subjects who have had prior exposure to any botulinum toxin for rhytids in the treatment area in the 6 months preceding study enrollment through the duration of the study.
• Subjects who have had a prior cosmetic procedure to improve rhytids in the treatment area (i.e.,rhytidectomy, CO2/erbium laser resurfacing, Thermage/Thermacool radiofrequency treatment)within 12 months or who have visible scars that may affect evaluation of response and/or quality of photography.
• Microdermabrasion, or prescription level glycolic acid treatments within 3 months prior to study participation or during the study.
• Active cut, wound, or infection on the skin.
• Oral Isotretinon within the past 12 months.
• Active HSV-1.
• History of keloids or hypertrophic scarring.
• Existing or history of skin malignancy in the treatment area during the past 12 months.
• Existing or history of skin disease in the treatment area during the past 12 months.
• History of collagen or vascular disease.
• Subjects who have implantable pacemaker, automatic implantable defibrillator/ cadioversor (AICD), or any other implantable electric device.
• Subjects who have used, within 30 days, any medication that can cause dermal hypersensitivity or affect skin characteristics.
• History of autoimmune disease.
• History of any disease that inhibits pain sensation.
• History of Diabetes I or II.
• Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication.
• Subjects who anticipate the need for surgery or overnight hospitalization during the study.
• Subjects who, in the Investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment or unreliability.
• Enrollment in any active study involving the use of investigational devices or drugs.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ellman International

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lisa Chipps, MD

Role: PRINCIPAL_INVESTIGATOR

Moy-Fincher-Chipps Facial Plastics/Dermatology

Locations

Moy-Fincher-Chipps Facial Plastics/Dermatology

Beverly Hills, California, United States

Countries

United States

Other Identifiers

PEL-09-02

Identifier Type: -

Identifier Source: org_study_id